Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Humans Carcinoma, Hepatocellular / drug therapy Bevacizumab / pharmacology Liver Neoplasms / drug therapy Prognosis Albumins

Journal

Targeted oncology

ISSN: 1776-260X

Titre abrégé: Target Oncol

Pays: France

ID NLM: 101270595

Informations de publication

Date de publication:
03 2023

Historique:

accepted: 17 02 2023

medline: 29 3 2023

pubmed: 16 3 2023

entrez: 15 3 2023

Statut: ppublish

Résumé

Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). We performed a real-world study to evaluate the impact of the IMbrave150 trial inclusion criteria on the safety and efficacy of treatment outside of clinical trials. We analyzed patients treated with atezolizumab plus bevacizumab for unresectable HCC from four different countries. No specific inclusion and exclusion criteria were applied, except for the absence of previous systemic therapies for HCC. The entire population was split into two groups according to concordance with the inclusion criteria as reported in the IMbrave150 trial in 'IMbrave150-in' and 'IMbrave150-out' patients, and safety and efficacy in the two groups of patients were evaluated. Overall, 766 patients were included in the analysis: 561/766 (73%) in the 'IMbrave150-in' group and 205/766 (27%) in the 'IMbrave150-out' group. Median overall survival (OS) and median progression-free survival (PFS) were 16.3 versus 14.3 months (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.35-0.65; p < 0.0001] and 8.3 versus 6.0 months (HR 0.79, 95% CI 0.63-0.99; p = 0.0431) in 'IMbrave150-in' and 'IMbrave150-out' patients, respectively. Multivariate analysis confirmed that patients included in the 'IMbrave150-in' group had significantly longer OS compared with patients included in the 'IMbrave150-out' group (HR 0.76, 95% CI 0.47-0.97; p = 0.0195). In 'IMbrave150-in' patients, the albumin-bilirubin (ALBI) grade was not associated with OS, whereas in 'IMbrave150-out' patients, those with ALBI grade 1 reported a significant benefit in terms of OS compared with those with ALBI grade 2 (16.7 vs. 5.9 months; HR 4.40, 95% CI 2.40-8.08; p > 0.0001). No statistically significant differences were reported in the 'IMbrave150-in' and 'IMbrave150-out' groups in terms of safety profile. Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.

Sections du résumé

BACKGROUND

Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC).

OBJECTIVE

We performed a real-world study to evaluate the impact of the IMbrave150 trial inclusion criteria on the safety and efficacy of treatment outside of clinical trials.

METHODS

We analyzed patients treated with atezolizumab plus bevacizumab for unresectable HCC from four different countries. No specific inclusion and exclusion criteria were applied, except for the absence of previous systemic therapies for HCC. The entire population was split into two groups according to concordance with the inclusion criteria as reported in the IMbrave150 trial in 'IMbrave150-in' and 'IMbrave150-out' patients, and safety and efficacy in the two groups of patients were evaluated.

RESULTS

Overall, 766 patients were included in the analysis: 561/766 (73%) in the 'IMbrave150-in' group and 205/766 (27%) in the 'IMbrave150-out' group. Median overall survival (OS) and median progression-free survival (PFS) were 16.3 versus 14.3 months (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.35-0.65; p < 0.0001] and 8.3 versus 6.0 months (HR 0.79, 95% CI 0.63-0.99; p = 0.0431) in 'IMbrave150-in' and 'IMbrave150-out' patients, respectively. Multivariate analysis confirmed that patients included in the 'IMbrave150-in' group had significantly longer OS compared with patients included in the 'IMbrave150-out' group (HR 0.76, 95% CI 0.47-0.97; p = 0.0195). In 'IMbrave150-in' patients, the albumin-bilirubin (ALBI) grade was not associated with OS, whereas in 'IMbrave150-out' patients, those with ALBI grade 1 reported a significant benefit in terms of OS compared with those with ALBI grade 2 (16.7 vs. 5.9 months; HR 4.40, 95% CI 2.40-8.08; p > 0.0001). No statistically significant differences were reported in the 'IMbrave150-in' and 'IMbrave150-out' groups in terms of safety profile.

CONCLUSION

Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.

Identifiants

DOI: 10.1007/s11523-023-00953-x PMID: 36920648

pubmed: 36920648

doi: 10.1007/s11523-023-00953-x

pii: 10.1007/s11523-023-00953-x

doi:

Substances chimiques

atezolizumab 52CMI0WC3Y

Bevacizumab 2S9ZZM9Q9V

Albumins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

221-233

Informations de copyright

Références

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3 .

doi: 10.1038/s41572-020-00240-3 pubmed: 33479224

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857 .

doi: 10.1056/NEJMoa0708857 pubmed: 18650514

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7 .

doi: 10.1016/S1470-2045(08)70285-7 pubmed: 19095497

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

doi: 10.1016/S0140-6736(18)30207-1 pubmed: 29433850

Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, et al. REal life study of LEnVAtiNib therapy for hepatocellular carcinoma: RELEVANT study. Liver Cancer. 2022;11(6):527–39. https://doi.org/10.1159/000525145 .

doi: 10.1159/000525145 pubmed: 36589723 pmcid: 9801178

Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, et al. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study. Hepatol Res. 2021;51(12):1229–41. https://doi.org/10.1111/hepr.13718 .

doi: 10.1111/hepr.13718 pubmed: 34591334

Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, et al. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int. 2021;41(6):1389–97. https://doi.org/10.1111/liv.14817 .

doi: 10.1111/liv.14817 pubmed: 33547848

Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, et al. Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy. Cancer Manag Res. 2021;13:9379–89. https://doi.org/10.2147/CMAR.S330195 .

doi: 10.2147/CMAR.S330195 pubmed: 34992463 pmcid: 8713715

Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, et al. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open. 2021;6(4):100190. https://doi.org/10.1016/j.esmoop.2021.100190 .

doi: 10.1016/j.esmoop.2021.100190 pubmed: 34144271 pmcid: 8219999

Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, et al. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res. 2022;52(12):1050–9. https://doi.org/10.1111/hepr.13824 .

doi: 10.1111/hepr.13824 pubmed: 35960789

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind. Phase III Trial J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307 .

doi: 10.1200/JCO.19.01307 pubmed: 31790344

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. https://doi.org/10.1016/S1470-2045(21)00604-5 .

doi: 10.1016/S1470-2045(21)00604-5 pubmed: 34914889

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745 .

doi: 10.1056/NEJMoa1915745 pubmed: 32402160

Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. J Clin Oncol. 2022;40(4 Suppl):379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379- .

doi: 10.1200/JCO.2022.40.4_suppl.379-

Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. https://doi.org/10.1016/S1470-2045(22)00326-6 .

doi: 10.1016/S1470-2045(22)00326-6 pubmed: 35798016

Finn R, et al. Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33(Suppl 7):S808–69. https://doi.org/10.1016/annonc/annonc1089 .

doi: 10.1016/annonc/annonc1089

Qin S, et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022;33(Suppl 7):S808–69. https://doi.org/10.1016/annonc/annonc1089 .

doi: 10.1016/annonc/annonc1089

Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020;6(12):e204930. https://doi.org/10.1001/jamaoncol.2020.4930 .

doi: 10.1001/jamaoncol.2020.4930 pubmed: 33090186 pmcid: 7582230

Vogel A, Rimassa L, Sun HC, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer. 2021;10(3):240–8. https://doi.org/10.1159/000515302 .

doi: 10.1159/000515302 pubmed: 34239810 pmcid: 8237801

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8. https://doi.org/10.1200/JCO.2014.57.9151 .

doi: 10.1200/JCO.2014.57.9151 pubmed: 25512453

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies [in Spanish, English]. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–2. https://doi.org/10.1016/j.ad.2019.05.009 .

doi: 10.1016/j.ad.2019.05.009 pubmed: 32891586

D’Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022;76(4):1000–12. https://doi.org/10.1002/hep.32468 .

doi: 10.1002/hep.32468 pubmed: 35313048

Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona MA, et al. Real-world data for lenvatinib in hepatocellular carcinoma (ELEVATOR): a retrospective multicenter study. Liver Cancer. 2022;11(3):219–32. https://doi.org/10.1159/000521746 .

doi: 10.1159/000521746 pubmed: 35949288 pmcid: 9218621

Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019;71(6):1175–83. https://doi.org/10.1016/j.jhep.2019.08.015 .

doi: 10.1016/j.jhep.2019.08.015 pubmed: 31449860

Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, et al. Efficacy and effect on liver functional reserve of atezolizumab and bevacizumab for Unresectable hepatocellular carcinoma in patients who do not meet eligibility criteria of IMbrave150. Cancers (Basel). 2022;14(16):3938. https://doi.org/10.3390/cancers14163938 .

doi: 10.3390/cancers14163938 pubmed: 36010930 pmcid: 9405784

Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325–36. https://doi.org/10.1159/000479984 .

doi: 10.1159/000479984 pubmed: 29234636 pmcid: 5704689

Rimini M, Rovesti G, Casadei-Gardini A. Child Pugh and ALBI grade: past, present or future? Ann Transl Med. 2020;8(17):1044. https://doi.org/10.21037/atm-20-3709 .

doi: 10.21037/atm-20-3709 pubmed: 33145263 pmcid: 7575984

de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022;14:17588359221080298. https://doi.org/10.1177/17588359221080298 .

doi: 10.1177/17588359221080298 pubmed: 35251317 pmcid: 8891886